TY - JOUR
T1 - Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-Nïb modified at the para position of the benzyl side chain (DPhe)
T2 - Importance for mouse melanocortin-3 receptor agonist versus antagonist activity
AU - Proneth, Bettina
AU - Pogozheva, Irina D.
AU - Portillo, Federico P.
AU - Mosberg, Henry I.
AU - Haskell-Luevano, Carrie
PY - 2008/9/25
Y1 - 2008/9/25
N2 - The melanocortin-3 and -4 receptors (MC3R, MC4R) have been implicated in energy homeostasis and obesity. Whereas the physiological role of the MC4R is extensively studied, little is known about the MC3R. One caveat is the limited availability of ligands that are selective for the MC3R. Previous studies identified Ac-His-DPhe(p-I)-Arg-Trp-NH2, which possessed partial agonist/antagonist pharmacology at the mMC3R while retaining full nanomolar agonist pharmacology at the mMC4R. These data allowed for the hypothesis that the DPhe position in melanocortin tetrapeptides can be used to examine ligand side-chain determinants important for differentiation of mMC3R agonist versus antagonist activity. A series of 15 DPhe7 modified Ac-His-DPhe 7-Arg-Trp-NH2 tetrapeptides has been synthesized and pharmacologically characterized. Most notable results include the identification of modifications that resulted in potent antagonists/partial agonists at the mMC3R and full, potent agonists at the mMC4R. These SAR studies provide experimental evidence that the molecular mechanism of antagonism at the mMC3R differentiates this subtype from the mMC4R.
AB - The melanocortin-3 and -4 receptors (MC3R, MC4R) have been implicated in energy homeostasis and obesity. Whereas the physiological role of the MC4R is extensively studied, little is known about the MC3R. One caveat is the limited availability of ligands that are selective for the MC3R. Previous studies identified Ac-His-DPhe(p-I)-Arg-Trp-NH2, which possessed partial agonist/antagonist pharmacology at the mMC3R while retaining full nanomolar agonist pharmacology at the mMC4R. These data allowed for the hypothesis that the DPhe position in melanocortin tetrapeptides can be used to examine ligand side-chain determinants important for differentiation of mMC3R agonist versus antagonist activity. A series of 15 DPhe7 modified Ac-His-DPhe 7-Arg-Trp-NH2 tetrapeptides has been synthesized and pharmacologically characterized. Most notable results include the identification of modifications that resulted in potent antagonists/partial agonists at the mMC3R and full, potent agonists at the mMC4R. These SAR studies provide experimental evidence that the molecular mechanism of antagonism at the mMC3R differentiates this subtype from the mMC4R.
UR - http://www.scopus.com/inward/record.url?scp=52449094727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=52449094727&partnerID=8YFLogxK
U2 - 10.1021/jm800291b
DO - 10.1021/jm800291b
M3 - Article
C2 - 18800761
AN - SCOPUS:52449094727
SN - 0022-2623
VL - 51
SP - 5585
EP - 5593
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 18
ER -